Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Acquisitions (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed Acquisitions for 15 consecutive years, with $1.7 billion as the latest value for Q4 2025.

  • Quarterly Acquisitions rose 3531.91% to $1.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.9 billion through Dec 2025, down 81.93% year-over-year, with the annual reading at $3.9 billion for FY2025, 81.93% down from the prior year.
  • Acquisitions for Q4 2025 was $1.7 billion at Bristol Myers Squibb, down from $1.9 billion in the prior quarter.
  • The five-year high for Acquisitions was $20.1 billion in Q1 2024, with the low at $35.0 million in Q1 2021.
  • Average Acquisitions over 5 years is $1.6 billion, with a median of $357.0 million recorded in 2021.
  • The sharpest move saw Acquisitions surged 25608.97% in 2024, then plummeted 99.61% in 2025.
  • Over 5 years, Acquisitions stood at $152.0 million in 2021, then decreased by 23.68% to $116.0 million in 2022, then soared by 400.86% to $581.0 million in 2023, then tumbled by 91.91% to $47.0 million in 2024, then soared by 3531.91% to $1.7 billion in 2025.
  • According to Business Quant data, Acquisitions over the past three periods came in at $1.7 billion, $1.9 billion, and $285.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.